Acticor Biotech Overview

  • Founded
  • 2013
Founded
  • Status
  • Private
  • Employees
  • 6
Employees
  • Latest Deal Type
  • Series B
  • Latest Deal Amount
  • $24.7M
Latest Deal Amount
  • Investors
  • 11

Acticor Biotech General Information

Description

Developer of an antithrombotic agent intended to provide the treatment of the acute phase of ischemic stroke. The company's biologic drug candidate ACT017 is a humanized fragment of monoclonal antibody which binds to GPVI and inhibits platelet adhesion and aggregation on collagen and polymerized fibrin, enabling clients to deliver proper drugs for strokes.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Primary Office
  • Hôpital Bichat-INSERM U1148
  • 46, rue Henri Huchard
  • 75018 Paris
  • France
+33 09 00 00 00 00

Acticor Biotech Timeline

2017201820192020
Financing Round
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Acticor Biotech Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Early Stage VC (Series B) 06-Nov-2019 $24.7M 000.00 000.00 Completed Clinical Trials - Phase 2
4. Early Stage VC 20-Dec-2017 00.000 00.000 000.00 Completed Pre-Clinical Trials
3. Early Stage VC 07-Feb-2017 00.000 00.000 00.000 Completed Pre-Clinical Trials
2. Seed Round 26-Jan-2015 $782K $782K 00.000 Completed Startup
1. Accelerator/Incubator Completed Startup
To view Acticor Biotech’s complete valuation and funding history, request access »

Acticor Biotech Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
ABSA 000,000 00.000000 0000.00 0000.00 00 0000.00 00.000
Preference 00,000 00.000000 000.00 000.00 00 000.00 0.000
Preference 28,037 $1.108602 $60.97 $60.97 1x $60.97 9.77%
Ordinary 17,552 $1.108602 $42.13 $42.13 1x $42.13 6.12%
To view Acticor Biotech’s complete cap table history, request access »

Acticor Biotech Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of an antithrombotic agent intended to provide the treatment of the acute phase of ischemic stroke. The compan
Biotechnology
Paris, France
6 As of 2016
000.00
00.00 0000-00-00
00000000000 000.00

00000000

boris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate v
0000000000000
Gaithersburg, MD
00 As of 0000
000.00
000 0000-00-00
00000000000 000.00

0000000

adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad mini
0000000000000
Portland, OR
0 As of 0000
0000000000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Acticor Biotech Competitors (16)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
NexImmune Venture Capital-Backed Gaithersburg, MD 00 000.00 00000000000 000.00
0000000 Accelerator/Incubator Backed Portland, OR 0 0000000000
0000 000000000000 Formerly VC-backed Cambridge, MA 00 00000 00000000 00000
00000000 Venture Capital-Backed Seal Beach, CA 000 00.00 000000000 - 00.00
00000000 Venture Capital-Backed San Carlos, CA 00 00000 00000000000 00000
You’re viewing 5 of 16 competitors. Get the full list »

Acticor Biotech Executive Team (8)

Name Title Board Seat Contact Info
Olivier Favre-Bulle Ph.D CMC Adviser
Gilles Avenard MD Co-Founder, President, Chief Executive Officer & Board Member
Eric Cohen Chief Financial Officer
Sophie Lebel-Binay Ph.D Chief Operating Officer & Chief Scientific Officer
Martine Jandrot-Perrus Ph.D Scientific Co-Founder
You’re viewing 5 of 8 executive team members. Get the full list »

Acticor Biotech Board Members (11)

Name Representing Role Since
Alain Parthoens Self Board Observer 000 0000
Catherine Boule Karista (France) Board Member 000 0000
Christophe Pasik Acticor Biotech Board Member 000 0000
Gilles Avenard MD Acticor Biotech Co-Founder, President, Chief Executive Officer & Board Member 000 0000
Guy Heynen MD Self Board Member 000 0000
You’re viewing 5 of 11 board members. Get the full list »

Acticor Biotech Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Acticor Biotech Investors (11)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
A&B (HK) Company Corporation Minority 000 0000 000000 0
ANAXAGO Real Estate Minority 000 0000 000000 0
China Medical System Corporation Minority 000 0000 000000 0
Go Capital PE/Buyout Minority 000 0000 000000 0
Mirae Asset Venture Investment PE/Buyout Minority 000 0000 000000 0
You’re viewing 5 of 11 investors. Get the full list »

Acticor Biotech Acquisitions (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
000000 06-Nov-2019 000000000000000000 Diagnostic Equipment 000000 0000000 00
To view Acticor Biotech’s complete acquisitions history, request access »